Fate Therapeutics(FATE)
SAN DIEGO, CA
Biotechnology1 H-1B visas (FY2023)Focus: Stem Cell-Modulating Therapeutics
Fate Therapeutics is a life sciences company focused on Stem Cell-Modulating Therapeutics.
Cell Therapy
Funding Stage
PUBLIC
Open Jobs
5
Pipeline & Clinical Trials
Genetically engineered NK cells
Hematological MalignancyClinical Trials (1)
NCT04093622Long-term Follow-Up Study Following Treatment With Fate Therapeutics' Engineered Cellular Immunotherapy
N/AMagnetic Resonance Imaging with Contrast
Alzheimer DiseaseClinical Trials (1)
NCT06877182Novel Neuroradiological Workflow for the Assisted DIAgnosis and Management of DEMentia with Artificial Intelligence
N/AAllogeneic natural killer
Advanced Solid TumorClinical Trials (1)
NCT04106167Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy
N/AFT819
Lymphoma, B-CellClinical Trials (1)
NCT04629729FT819 in Subjects With B-cell Malignancies
Phase 1FT825
Advanced Solid TumorClinical Trials (1)
NCT06241456FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors
Phase 1FT576
Multiple MyelomaClinical Trials (1)
NCT05182073FT576 in Subjects With Multiple Myeloma
Phase 1Phase 1
Clinical Trials (1)
NCT03841110FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors
Phase 1Biological: ProHema-CB
Hematologic MalignanciesClinical Trials (1)
NCT02354417A Phase 1 Trial of a Single ProHema® CB Product for Pediatric Patients With Hematologic Malignancies
Phase 1ProHema-CB Transplant
Metabolic DisordersClinical Trials (1)
NCT02354443A Trial of a Single ProHema-CB Product Transplant in Pediatric Patients With Inherited Metabolic Disorders
Phase 1Phase 1
Clinical Trials (1)
NCT07216105FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
Phase 1Phase 1
Clinical Trials (1)
NCT05950334FT522 With Rituximab in Relapsed/Refractory B-Cell Lymphoma (FT522-101)
Phase 1Clinical Trials (1)
NCT06308978A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
Phase 1FATE-NK100
HER2 Positive Gastric CancerClinical Trials (1)
NCT03319459FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors
Phase 1Phase 1
Clinical Trials (1)
NCT05934097FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma
Phase 1Phase 1
Clinical Trials (1)
NCT04023071FT516 in Subjects With Advanced Hematologic Malignancies
Phase 1Phase 1
Clinical Trials (1)
NCT05395052FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors
Phase 1FT538
Solid Tumor, AdultClinical Trials (1)
NCT05069935FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors
Phase 1Phase 1
Clinical Trials (1)
NCT04614636FT538 in Subjects With Advanced Hematologic Malignancies
Phase 1FT516
Solid Tumor, AdultClinical Trials (1)
NCT04551885FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors
Phase 1Fludarabine
Hematologic MalignanciesClinical Trials (1)
NCT00890500Safety and Efficacy of ProHema Modulated Umbilical Cord Blood Units in Subjects With Hematologic Malignancies.
Phase 1FT596
Lymphoma, B-CellClinical Trials (1)
NCT04245722FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies
Phase 1Single FT1050 treated UCB unit
Non-Hodgkin's Lymphoma (NHL)Clinical Trials (1)
NCT01527838Single Treatment With FT1050 of an Ex-vivo Modulated Umbilical Cord Blood Unit
Phase 1ProTmune
Hematologic MalignanciesClinical Trials (1)
NCT02743351Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies
Phase 1/2ProHema-CB
Hematologic MalignanciesClinical Trials (1)
NCT01627314The PUMA Trial is a Trial of a Single ProHema Modulated-Cord Blood (CB) Unit as Part of a Double CB Transplant in Patients With Hematologic Malignancies.
Phase 2Open Jobs (5)
Senior Director, Supply Chain
San Diego, CA
Supply Chain4d ago
Senior Manager / Associate Director, Project Management
San Diego, CA
General & Administrative4d ago
Medical Director, Autoimmunity
San Diego, CA
Clinical6d ago
Manager, Clinical Site Budgets
San Diego, CA
Clinical1mo ago
Senior Manager/Manager, Manufacturing
San Diego, CA
Supply Chain5mo ago
Interview Prep Quick Facts
Portfolio: 24 clinical trials
H-1B (2023): 1 approval
SEC Filings: 2 available
Open Roles: 5 active jobs
Financials (FY2025)
Revenue
$14M79%
R&D Spend
$135M(990%)22%
Net Income
-$186MCash
$36MHiring Trend
Stable
5
Open Roles
+3
Added
-1
Filled/Removed
Based on last 4 crawl cycles
Visa Sponsorship
Sponsors Work Visas
H-1B Petitions (FY2023)
1
Approved
0
Denied
100%
Rate
Source: USCIS H-1B Employer Data Hub